Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage

Evolutionary Applications

Volumn 5, Issue 6, 2012, Pages 583-592

  Escobar Páramo, Patricia ^b   Gougat Barbera, Claire ^a   Hochberg, Michael E ^a  

^a INSTITUT DES SCIENCES DE L EVOLUTION   (France)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Antibiotic resistance; Bacteria; Experimental evolution; Hypermutator; Phage therapy; Pseudomonas

Indexed keywords

EID: 84866032343     PISSN: 17524563     EISSN: 17524571     Source Type: Journal    
DOI: 10.1111/j.1752-4571.2012.00248.x     Document Type: Article

References (48)

1. Arnaut-Rollier, I., L. Vauterin, P. De Vos, D. L. Massart, L. A. Devriese, L. De Zutter, and J. Van Hoof. 1999. A numerical taxonomic study of the Pseudomonas flora isolated from poultry meat. Journal of Applied Microbiology 87:15-28.
2. Baquero, F., M. C. Negri, M. I. Morosini, and J. Blasquez. 1998. Antibiotic-Selective environments. Clinical Infectious Diseases 27:S5-S11.
3. Bell, G., and S. Collins. 2008. Adaptation, extinction and global change. Evolutionary Applications 1:3-16.
4. Brockhurst, M. A., A. D. Morgan, A. Fenton, and A. Buckling. 2007. Experimental coevolution with bacteria and phage The Pseudomonas fluorescens-phi2 model. Infection, Genetics and Evolution 7:547-552.
5. Buckling, A., and P. B. Rainey. 2002. Antagonistic coevolution between a bacterium and a bacteriophage. Proceedings. Biological sciences/The Royal Society 269:931-936.
6. Cairns, B. J., and R. J. Payne. 2008. Bacteriophage therapy and the mutant selection window. Antimicrobial Agents and Chemotherapy 52:4344-4350.
7. Cairns, B. J., and R. J. Payne. 2009. Sudden increase in listeriosis rates in England and Wales, 2001 and 2003. Emerging Infectious Diseases 15:465-468.
8. Cairns, B. J., A. R. Timms, V. A. Jansen, I. F. Connerton, and R. J. Payne. 2009. Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathogens 5:e1000253.
9. Capparelli, R., M. Parlato, G. Borriello, P. Salvatore, and D. Iannelli. 2007. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrobial Agents and Chemotherapy 51:2765-2763.
10. Chanishvili, N., T. Chanishvili, M. Tediashvili, and P. A. Barrow. 2001. Phages and their application against drug-resistant bacteria. Journal of Chemical Technology and Biotechnology 76:689-699.
11. D'Agata, E. M. C., M. Dupont-Rouzeyrol, P. MAgal, D. Olivier, and S. Ruan. 2008. The impact of different antibiotic regimens on the emergence of antimicrobial-resistant bacteria. PLoS ONE 3:e4036.
12. Denamur, E., S. Bonacorsi, A. Giraud, P. Duriez, F. Hilali, C. Amorin, E. Bingen et al. 2002. High frequency of mutator strains among human uropathogenic Escherichia coli isolates. Journal of Bacteriology 184:605-609.
13. Dogan, B., and K. J. Boor. 2003. Genetic diversity and spoilage potentials among Pseudomonas spp. isolated from fluid milk products and dairy processing plants. Applied and Environmental Microbiology 69:130-138.
14. Dunne, W. M. 2002. Bacterial adhesion: seen any good biofilms lately? Clinical Microbiology Reviews 15:155-166.
15. Escobar-Páramo, P., N. Faivre, A. Buckling, C. Gougat-Barbera, and M. E. Hochberg. 2009. Persistence of costly novel genes in the absence of positive selection. Journal of Evolutionary Biology 22:536-543.
16. Hall-Stoodley, L., J. W. Costerton, and P. Stoodley. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nature Reviews Microbiology 2:95-108.
17. Hoffman, L. R., D. A. D'Argenio, M. J. MacCoss, Z. Zhang, R. A. Jones, and S. I. Miller. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171-1175.
18. Hung, C.-H., C.-F. Kuo, C.-H. Wang, C.-M. Wu, and N. Tsao. 2011. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacterimia in mice. Antimicrobial Agents and Chemotherapy 55:1358-1365.
19. Jin, D. J., and C. A. Gross. 1989. Characterization of the pleiotropic phenotypes of rifampin-resistant rpoB mutants of Escherichia coli. Journal of Bacteriology 171:5229-5231.
20. Jin, D. J., and Y. N. Zhou. 1996. Mutational analysis of structure-function relationship of RNA polymerase in Escherichia coli. Methods in Enzymology 273:300-319.
21. JMP® 19892007. Version 7. SAS Institute Inc., Cary, NC.
22. Karunakaran, P., and J. Davies. 2000. Genetic antagonism and hypermutability in Mycobacterium smegmatis. Journal of Bacteriology 182:3331-3335.
23. Kutateladze, M., and R. Adamia. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends in Biotechnology 28:591-595.
24. Kutter, E. 2009. Phage therapy: bacteriophages as natural, self-replicating antimicrobials. In: E. Goldman, ed. Practical Handbook of Microbiology, 2nd edn, pp. 713-730. CRC Press, Boca Raton, FL.
25. Kutter, E., D. De Vos, G. Gvasalia, Z. Alavidez, L. Gogokhia, S. Kuhl, and S. T. Abedon. 2010. Phage therapy in clinical practice: treatment of human infections. Current Pharmaceutical Biotechnology 11:69-86.
26. Larkin, M. A., G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettingan, H. McWilliam, F. Valentin et al. 2007. ClustalW and ClustalX version 2. Bioinformatics 23:2947-2948.
27. Lenski, R. E. 1998 Bacterial evolution and the cost of antibiotic resistance. International Microbiology 1:265-270.
28. Levin, B. R., and J. J. Bull. 2004. Population and evolutionary dynamics of phage therapy. Nature Reviews Microbiology 2:166-173.
29. Levin, B. R., V. Perrot, and N. Walker. 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-997.
30. Matic, I., M. Radman, F. Taddei, B. Picard, C. Doit, E. Bingen, E. Denamur et al. 1997. Highly variable mutation rates in commensal and pathogenic Escherichia coli. Science 277:1833-1834.
31. Matsuzaki, S., M. Yasuda, H. Nishikawa, M. Kuroda, T. Ujihara, T. Shuin, Y. Shen et al. 2003. Experimental protection of mice against lethal Staphylococcus aureus infection by a novel bacteriophage phi MR11. Journal of Infectious Diseases 187:613-624.
32. Mavrodi, D. V., W. Blankenfeldt, and L. S. Thomashow. 2006. Phenazine compounds in fluorescent Pseudomonas spp. biosynthesis and regulation. Annual review of Phytopathology 44:417-445.
33. Mizoguchi, K., M. Morita, C. R. Fischer, M. Yoichi, Y. Tanji, and H. Unno. 2003. Coevolution of bacteriophage PP01 and Escherichia coli O157:H7 in continuous culture. Applied and Environmental Microbiology 69:170-176.
34. Pal, C., M. D. Macia, A. Oliver, I. Schachar, and A. Buckling. 2007. Coevolution with viruses drives the evolution of bacterial mutation rates. Nature 450:1079-1081.
35. Payne, R. J., D. Phil, and V. A. Jansen. 2000. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clinical Pharmacology and Therapeutics 68:225-230.
36. Perron, G. G., A. R. Hall, and A. Buckling. 2010. Hypermutability and compensatory adaptation in antibiotic-resistant bacteria. The American Naturalist 176:303-311.
37. Poullain, V., S. Gandon, M. A. Brockhurst, A. Buckling, and M. E. Hochberg. 2008. The evolution of specificity in evolving and coevolving antagonistic interactions between a bacteria and its phage. Evolution 62:1-11.
38. Rainey, P. B., and M. J. Bailey. 1996. Physical and genetic map of the Pseudomonas fluorescens SBW25 chromosome. Molecular Microbiology 19:521-533.
39. Rainey, P. B., and M. Travisano. 1998. Adaptive radiation in a heterogeneous environment. Nature 394:69-72.
40. Reid, P. 1971. Isolation of cold sensitive rifampin resistant RNA polymerase mutants of Escherichia coli. Biochemical and Biophysical Research Communications 44:737-744.
41. Ryu, J. I. 1978. Pleiotropic effect of a rifampin-resistant mutation in Bacills subtilis. Journal of Bacteriology 135:408-414.
42. Schrag, S. J., V. Perrot, and B. R. Levin. 1997. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proceedings of the Royal Society of London. Series B 264:12871291.
43. Schwarz, T. F. R., S. M. Yeast, P. Connolly, and D. J. McConnell. 1981. Altered transcriptional termination in a rifampicin-resistant mutant of Escherichia coli which inhibit the growth of bacteriopaghe T7. Molecular and General Genetics 183:181-186.
44. Sillankorva, S., R. Oliveira, M. J. Vieira, I. W. Sutherland, and J. Azeredo. 2004. Bacteriophage phiS infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 20:133-138.
45. Snyder, L. 1972. An RNA polymerase mutant of Escherichia coli defective in the T4 viral transcription program. Virology 50:396-403.
46. Spiers, A. J., J. Bohannon, S. M. Gehrig, and P. B. Rainey. 2003. Biofilm formation at the air-liquid interface by the Pseudomonas fluorescens SBW25 wrinkly spreader requires an acetylated form of cellulose. Molecular Microbiology 50:15-27.
47. Stewart, P., and J. W. Costerton. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
48. Tayeb, L. A., E. Ageron, F. Grimont, and P. A. D. Grimont. 2005. Molecular phylogeny of the genus Pseudomonas based on rpoB sequences and application for the identification of isolates. Research in Microbiology 156:763-773.